LKFT NASDAQ
Lakefront Biotherapeutics N.V.
1W: -3.1%
1M: -2.5%
YTD: -1.2%
$28.15
+0.02 (+0.07%)
Weekly Expected Move ±3.4%
$26
$27
$28
$29
$30
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.9B
52W Range26.42-37.78
Volume124,845
Avg Volume173,627
Beta0.12
Dividend—
Analyst Ratings
Company Info
CEOHenry O. Gosebruch
Employees452
SectorHealthcare
IndustryBiotechnology
IPO Date2005-05-05
Websitegalapagos.com
SchaliEnhoevedreef 20 T
Mechelen 2800
BE
Mechelen 2800
BE
32 1 534 29 00
About Lakefront Biotherapeutics N.V.
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Latest News
No recent news
Recent Insider Trades
No insider trades found